1-4 of 4
Samantha Pazienza
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Safety and Preliminary Efficacy of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) in Patients with Relapsed/Refractory Mantle Cell Lymphoma

Austin I Kim, Philippe Armand, Robert A. Redd, Megan Forsyth, Paul Branch, Samantha Pazienza, Lisa Brennan, Victoria Patterson, Susan M Waisgerber, Reid W. Merryman, David C Fisher, Christine E. Ryan, Inhye E Ahn, Jennifer L Crombie, Oreofe O. Odejide, Ann LaCasce, Caron A Jacobson, Eric Jacobsen, Erin M Parry, Matthew S Davids, Jennifer R. Brown, Arnold S. Freedman, Peter A. Riedell, Mark Alan Murakami
Journal: Blood
Blood (2023) 142 (Supplement 1): 3031.
https://doi.org/10.1182/blood-2023-173103
Published: 2023
Journal Articles

Updated Results from a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease

Christine E. Ryan, Benjamin L. Lampson, Svitlana Tyekucheva, Liam R. Hackett, Yue Ren, Samantha J. Shupe, Stacey M. Fernandes, Jennifer L. Crombie, Samuel Ng, Austin I. Kim, Inhye E. Ahn, Matthew J Weinstock, Samantha Pazienza, Josie S. Montegaard, Victoria Patterson, Caron A. Jacobson, Ann S. LaCasce, Philippe Armand, David C. Fisher, Jon E. Arnason, Steve Lo, Adam Olszewski, Jennifer R. Brown, Matthew S. Davids
Journal: Blood
Blood (2022) 140 (Supplement 1): 837–838.
https://doi.org/10.1182/blood-2022-168003
Published: 2022
Journal Articles

Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome

Clinical Trials & Observations Brief Report
Matthew S. Davids, Kerry A. Rogers, Svitlana Tyekucheva, Zixu Wang, Samantha Pazienza, Sarah K. Renner, Josie Montegaard, Udochukwu Ihuoma, Timothy Z. Lehmberg, Erin M. Parry, Catherine J. Wu, Caron A. Jacobson, David C. Fisher, Philip A. Thompson, Jennifer R. Brown
Journal: Blood
Blood (2022) 139 (5): 686–689.
https://doi.org/10.1182/blood.2021011386
Published: 2022
Includes: Supplemental data
Journal Articles

Updated Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab (AVO) for Frontline Treatment of Chronic Lymphocytic Leukemia (CLL)

Matthew S. Davids, MD, Benjamin L. Lampson, MD PhD, Svitlana Tyekucheva, PhD, Jennifer L. Crombie, MD, Samuel Ng, MD PhD, Austin I. Kim, MD, Matthew Weinstock, MD, Jessica Lowney, Samantha Pazienza, Josie Montegaard, NP, Victoria Patterson, BSN, RN, Caron A. Jacobson, MD, Ann S. LaCasce, MD MSc, Philippe Armand, MD PhD, Jon E. Arnason, MD, David C. Fisher, MD, Jennifer R. Brown, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 20–21.
https://doi.org/10.1182/blood-2020-139864
Published: 2020